Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine, has announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. Now available for clinicians to order, the IPS test is a multimodal biomarker designed to serve as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are candidates for immune checkpoint inhibitor (ICI) therapy.
Tempus is presenting the results of its validation study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The study demonstrated that patients with a high IPS score (IPS-High) were more likely to experience an overall survival benefit from ICI-based therapy compared to those with a low IPS score (IPS-Low), with a hazard ratio of 0.45. This validation highlights the potential of IPS to help guide treatment decisions and improve outcomes for patients undergoing immunotherapy.
In a retrospective study of 1,600 adult patients with 19 different types of metastatic or stage IV solid tumors from Tempus’ de-identified real-world database, the IPS test demonstrated significant prognostic value. The study showed that IPS-High patients had a higher likelihood of overall survival benefits from ICI therapy compared to IPS-Low patients, with a hazard ratio of 0.45. Importantly, IPS was found to have independent prognostic utility from established biomarkers such as tumor mutational burden (TMB), PD-L1 immunohistochemistry (IHC), and microsatellite instability (MSI), offering a unique and complementary approach to cancer treatment decision-making.
“Tempus is proud to introduce our first multimodal algorithm in the immunotherapy space,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “The IPS test empowers clinicians with data-driven insights that can inform treatment decisions and help identify patients who are most likely to benefit from immunotherapy, improving patient outcomes.”
The IPS test scores patients on a scale from 0 to 100, classifying them as either IPS-High or IPS-Low. It assesses immunotherapy-related biomarkers from both DNA and RNA sequencing results, making it a powerful addition to clinical practice. The test is designed to support not only patient care but also life sciences research, facilitating the expansion of indications for immune checkpoint inhibitors and enhancing patient selection criteria.
“This study shows that IPS scoring can identify patients who may benefit from immune checkpoint inhibitors, regardless of standard biomarkers like PD-L1 IHC and TMB,” said Sandip Patel, MD, Professor at UC San Diego Health. “IPS offers a deeper understanding of tumor-intrinsic sensitivity to immune checkpoint blockade and can help clinicians make better decisions for immunotherapy patients based on existing DNA and RNA sequencing data.”
About Tempus
Tempus is a technology company driving precision medicine through the application of artificial intelligence in healthcare. With one of the world’s largest multimodal data libraries and a powerful operating system to make that data actionable, Tempus delivers AI-powered solutions to help physicians provide personalized patient care. Tempus also supports the discovery, development, and delivery of optimal therapeutics, aiming to improve patient outcomes by leveraging insights gained from its growing data set.
